Tuesday - March 03, 2026

Category Archives: Marketing & Sales

Common Warts Market: Expanding Revenue Landscape to 2034 – DelveInsight | Nielsen BioSciences, Verrica Pharmaceutical, Kino Pharma, Iwaki Pharma, Aclaris Therapeutics

The Key Common Warts Companies in the market include – Nielsen BioSciences, Verrica Pharmaceutical, Kino Pharma/ Iwaki Pharmaceutical, Aclaris Therapeutics, Inc., KinoPharma Inc., ViroXis Corporation, Maruho Co., Ltd., Veradermics, Inc., Graceway Pharmaceuticals, LLC, MEDA Pharma, LEO Pharma, and others.   … Continue reading →

Stargardt Disease Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Ocugen, Kubota Vision Inc, Nanoscope Therapeutics, RBP4 Pty Ltd, Stargazer Pharma, Belite Bio, Alkeus Pharma

The Key Stargardt Disease Companies in the market include – Ocugen, Kubota Vision Inc, Nanoscope Therapeutics Inc., RBP4 Pty Ltd, Stargazer Pharmaceuticals, Inc., Belite Bio, Inc, Alkeus Pharmaceuticals, Inc., IVERIC bio, Inc., Kubota Vision Inc., Astellas Institute, Nanoscope Therapeutics, Alkeus … Continue reading →

Sarcopenia Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Oncocross, Biophytis, MyMD Pharmaceuticals, Novartis, Regeneron Pharma, Merck

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Sarcopenia pipeline constitutes 18+ key companies continuously working towards developing 20+ Sarcopenia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. “Sarcopenia … Continue reading →

Chronic Rhinosinusitis with Nasal Polyps Competitive Landscape Assessment 2026: FDA Approvals, Clinical trial, Emerging Therapies, Mechanism of Action, and Route of Administration | DelveInsight

Chronic Rhinosinusitis with Nasal Polyps Clinical Trial Companies active in the Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) space include Keymed Biosciences, Connect Biopharma, AstraZeneca, Amgen, Pfizer, Trellis Bioscience LLC, GlaxoSmithKline, Gossamer Bio, Biohaven Pharmaceuticals, Insmed Incorporated, Lyra Therapeutics, and several … Continue reading →

Vasculitis Clinical Trials Analysis 2026: Competitive Landscape, Regulatory Updates, Emerging Therapies, Mechanisms of Action, and Routes of Administration | DelveInsight

Vasculitis Pipeline Leading companies involved in the Vasculitis therapeutic space include R-Pharm Overseas, AbbVie, Toleranzia, Ambulero, Visterra, CytoDyn, ChemoCentryx, Hoffmann-La Roche, GlaxoSmithKline, Vifor Pharma, Beijing Defengrei Biotechnology, InflaRx, Janssen Biotech, Novartis, Oxitope Pharma, Eli Lilly and Company, Travere Therapeutics, Caladrius … Continue reading →

Diagnostic Imaging Equipment Market to Reach USD 82.26 Billion by 2034, Growing at 5.39% CAGR from 2026-2034 Amid Rising Chronic Disease Burden and AI-Driven Innovation, analyses DelveInsight

Diagnostic Imaging Equipment Market The global diagnostic imaging equipment market is projected to grow from USD 51,560.07 million in 2025. Also, Market growth is largely attributed to the increasing burden of chronic illnesses such as cardiovascular diseases, cancer, neurological disorders, … Continue reading →

Juvenile Idiopathic Arthritis Market Poised to Grow at 5.6% CAGR Through 2036 | DelveInsight

Juvenile Idiopathic Arthritis Market Leading Juvenile Idiopathic Arthritis Companies include Bristol-Myers Squibb, UCB Biopharma, Novartis, AbbVie, Sanofi, Regeneron Pharmaceuticals, Janssen Pharmaceutical, Eli Lilly, Sobi, Pfizer, and others The Juvenile Idiopathic Arthritis (JIA) market is witnessing consistent expansion, fueled by increasing … Continue reading →

Orforglipron Market Set for Transformational Growth Across Obesity and Type 2 Diabetes Landscape Through 2034 | DelveInsight

Orforglipron Market Global momentum builds around investigational oral GLP-1 receptor agonist Orforglipron as Phase III data signal strong commercial and clinical potential The global metabolic disorder treatment landscape is on the brink of significant transformation as Orforglipron, an investigational once-daily … Continue reading →

Mindsec Shares New Data Residency Report: Why 40% of Canadian CISOs Are Repatriating Compliance Data from US Vendors

Mindsec, a Canada-based security compliance automation platform, has released a new Data Residency Report highlighting a significant shift in compliance data strategy among Canadian organizations. According to the report, approximately 40% of Canadian Chief Information Security Officers (CISOs) are actively … Continue reading →